"Antisickling Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
| Descriptor ID |
D000986
|
| MeSH Number(s) |
D27.505.954.502.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antisickling Agents".
Below are MeSH descriptors whose meaning is more specific than "Antisickling Agents".
This graph shows the total number of publications written about "Antisickling Agents" by people in this website by year, and whether "Antisickling Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antisickling Agents" by people in Profiles.
-
Pittman DD, Hines PC, Beidler D, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020.
-
Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS One. 2013; 8(2):e55709.
-
Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer. 2013 Apr; 60(4):653-8.
-
Ballas SK, McCarthy WF, Guo N, DeCastro L, Bellevue R, Barton BA, Waclawiw MA. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009 Oct; 101(10):1046-51.
-
Smith WR, Bauserman RL, Ballas SK, McCarthy WF, Steinberg MH, Swerdlow PS, Waclawiw MA, Barton BA. Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain. 2009 Nov; 146(1-2):91-8.
-
Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006 Aug 31; 4:59.
-
Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996 Oct; 129(4):559-65.
-
Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, Alper SL, Platt OS. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1996 Mar 01; 97(5):1227-34.